Soleno Therapeutics Inc (SLNO) Stock Price, Quote & News

Company Profile

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was i...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 213 8444

Fax: 650 213 8383

Website: soleno.life

Address:

100 Marine Parkway, Suite 400, Redwood City, United States

biolevity Jul. 24 at 1:33 PM

$RZLT could be the $SLNO

0 · Reply

DaysofThunder Jul. 24 at 12:56 PM

$ACAD valued at 3.9B making 250M a qtr while $SLNO valued at 4.6B hoping to being in 33M in Q2. So I guess if ACAD data in PWS is positive, this should I go up to at least 8B.

0 · Reply

Stocks4thought Jul. 23 at 6:11 PM

$IMMX Super pent up overhang- thought we'd erased it- but there you saw its exhausting $3.20 going to > $4 now- in about 3 weeks or less. $SLNO

0 · Reply

MikiTrader Jul. 19 at 2:54 AM

$IXHL I’m all about the $SLNO style rerating rocket ride.

0 · Reply

Stocks4thought Jul. 18 at 3:52 PM

$ATYR We told you everyone loves $^6===============ot $SLNO $IMMX $STOK $TCRX

0 · Reply

biolover Jul. 15 at 6:04 PM

$GPCR $RYTM $SLNO $SRRK $VKTX RYTM drug ( which is simple receptor inhibitor ) is for $400 000 per year for wt loss and not to cure the condition . This is the woke mind virus in health system. Don’t know who would feel comfortable from BP with this price long term.

2 · Reply

Quantumup Jul. 15 at 5:36 PM

BofA⬆️ $RYTM PT to $109 from $95 after speaking w/ KOL and said, "Improved tolerability with next-gen oral could expand HO market oppy; Reit. Buy—Positive readthrough to next-gen weekly MC4R agonist." $VKTX $GPCR LLY NVO $SRRK $SLNO AARD BofA additionally said in its note to investors:

0 · Reply

Night_Owl_Biotech Jul. 13 at 9:42 PM

The $VRNA M&A exit within 13 months of FDA approval underscores the overwhelming history the sooner new comm'l-stage bios exit the better for shareholders. The attachment lists all new comm'l-stage bio M&A for those with 1st approvals since 1/1/12. Of the 16 oncology focused M&A sales where shareholders saw gains, 14 were sold within 2 years. 7 of the 8 sold at losses (v. share prices at FDA approval) waited more than 2 years to sell. The phenomenon is the same in commercial-stage non-oncology except the window is 3 years. 2 of every 3 that have not been sold (i.e. M&A candidates) trade lower today than at the time of FDA approval. $BPMC is an outlier that waited over 2 years from 1st approval to sell. However, BPMC did sell within 2 years of Ayvakit's expansion into ISM (its biggest TAM). Even TSRO sold within 2 years of Zejula's approval (its biggest TAM) so the outliers do not appear true outliers. Of course things change too. This is not investment advice. $INSM $SLNO $INSM

3 · Reply

EdwardTeach Jul. 11 at 6:40 PM

$LSTA $SLNO $VKTX $BWAY $SGMT There's no reason why this isn't over $4...glta

0 · Reply

IN0V8 Jul. 11 at 5:40 PM

$SLNO Opportunity Baird raises target price to $121 from $105

1 · Reply

Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Jul 10, 2025, 6:01 AM EDT - 22 days ago

Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock

Jul 10, 2025, 6:00 AM EDT - 22 days ago

Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025

Jun 20, 2025, 8:00 AM EDT - 6 weeks ago

Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference

May 22, 2025, 5:32 PM EDT - 2 months ago

Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome

May 20, 2025, 4:05 PM EDT - 2 months ago

Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome

May 7, 2025, 10:30 PM EDT - 3 months ago

Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:01 PM EDT - 3 months ago

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

Apr 23, 2025, 7:00 AM EDT - 3 months ago

Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET

Apr 14, 2025, 7:00 AM EDT - 3 months ago

Soleno Therapeutics Announces VYKAT(TM) XR Launch

Mar 27, 2025, 8:11 AM EDT - 4 months ago

Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder

Mar 26, 2025, 5:15 PM EDT - 4 months ago

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

Jan 29, 2025, 4:05 PM EST - 6 months ago

Soleno Therapeutics to Participate in Upcoming February Investor Conferences

Dec 17, 2024, 4:05 PM EST - 8 months ago

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

Nov 27, 2024, 8:00 AM EST - 8 months ago

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 8:30 AM EST - 8 months ago

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Nov 14, 2024, 4:05 PM EST - 9 months ago

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

Oct 10, 2024, 2:53 PM EDT - 10 months ago

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Oct 8, 2024, 6:51 PM EDT - 10 months ago

SLNO Stock Rises as Prader-Willi Treatment Nears FDA Approval

Oct 3, 2024, 12:03 PM EDT - 10 months ago

Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc

JHG

Sep 16, 2024, 4:05 PM EDT - 11 months ago

Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Aug 27, 2024, 1:00 PM EDT - 1 year ago

Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Aug 19, 2024, 4:17 PM EDT - 1 year ago

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

May 22, 2024, 4:05 PM EDT - 1 year ago

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

May 22, 2024, 8:00 AM EDT - 1 year ago

Soleno Therapeutics to Participate in Upcoming Investor Conferences

May 15, 2024, 8:00 AM EDT - 1 year ago

Soleno Therapeutics Stands with the Prader-Willi Syndrome Community

May 9, 2024, 4:05 PM EDT - 1 year ago

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 2, 2024, 10:32 PM EDT - 1 year ago

Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock

May 2, 2024, 4:01 PM EDT - 1 year ago

Soleno Therapeutics Announces Proposed Public Offering of Common Stock

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome

Apr 29, 2024, 4:02 PM EDT - 1 year ago

Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Mar 6, 2024, 4:05 PM EST - 1 year ago

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 22, 2024, 8:00 AM EST - 1 year ago

Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 1, 2024, 8:00 AM EST - 1 year ago

Soleno Therapeutics to Present at Upcoming February Investor Conferences

Jan 24, 2024, 8:00 AM EST - 1 year ago

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Jan 22, 2024, 10:42 PM EST - 1 year ago

Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families

ACAD

Dec 27, 2023, 2:46 PM EST - 1 year ago

The best-performing stock of the year rose nearly 10-fold, while the second-best averted disaster to surge 1,000% in a wild 2023

CVNA

Nov 26, 2023, 10:47 AM EST - 1 year ago

Soleno Therapeutics: Impressive Data, But Never Forget Amarin

Nov 7, 2023, 8:00 AM EST - 1 year ago

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 6, 2023, 8:00 AM EST - 1 year ago

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome

Oct 4, 2023, 6:16 PM EDT - 1 year ago

Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium

Oct 4, 2023, 4:05 PM EDT - 1 year ago

Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium

Oct 2, 2023, 4:05 PM EDT - 1 year ago

Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 28, 2023, 8:30 AM EDT - 2 years ago

Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

Sep 27, 2023, 4:01 PM EDT - 2 years ago

Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

Sep 27, 2023, 1:28 PM EDT - 2 years ago

Soleno Stock Dives After Its Meteoric Rise

biolevity Jul. 24 at 1:33 PM

$RZLT could be the $SLNO

0 · Reply

DaysofThunder Jul. 24 at 12:56 PM

$ACAD valued at 3.9B making 250M a qtr while $SLNO valued at 4.6B hoping to being in 33M in Q2. So I guess if ACAD data in PWS is positive, this should I go up to at least 8B.

0 · Reply

Stocks4thought Jul. 23 at 6:11 PM

$IMMX Super pent up overhang- thought we'd erased it- but there you saw its exhausting $3.20 going to > $4 now- in about 3 weeks or less. $SLNO

0 · Reply

MikiTrader Jul. 19 at 2:54 AM

$IXHL I’m all about the $SLNO style rerating rocket ride.

0 · Reply

Stocks4thought Jul. 18 at 3:52 PM

$ATYR We told you everyone loves $^6===============ot $SLNO $IMMX $STOK $TCRX

0 · Reply

biolover Jul. 15 at 6:04 PM

2 · Reply

Quantumup Jul. 15 at 5:36 PM

0 · Reply

Night_Owl_Biotech Jul. 13 at 9:42 PM

3 · Reply

EdwardTeach Jul. 11 at 6:40 PM

$LSTA $SLNO $VKTX $BWAY $SGMT There's no reason why this isn't over $4...glta

0 · Reply

IN0V8 Jul. 11 at 5:40 PM

$SLNO Opportunity Baird raises target price to $121 from $105

1 · Reply

Quantumup Jul. 11 at 5:39 PM

Goldman Sachs, on 7/10, resumed $RYTM Buy/$97 $SLNO $AARD LLY $VKTX $GPCR SRRK Goldman Sachs said in their note:

0 · Reply

Stocks4thought Jul. 11 at 4:45 PM

$LSTA ASCEND trial data for Lisata Therapeutics’ certepetide in metastatic pancreatic cancer (mPDAC) is clinically meaningful and scientifically promising Cohort B (newest update – June 2025) 6-month progression-free survival (6MPFS): Certepetide arm: 60.8% Placebo arm: 25% +35.8% absolute improvement — this is very strong for mPDAC. Median PFS: Certepetide: 7.5 months Placebo: 4.7 months ~60% relative improvement — clinically meaningful. Objective Response Rate (ORR): Certepetide: 45.2% Placebo: 19% More than doubling the response rate, which is rare in pancreatic cancer. ot $SLNO $VKTX $BWAY $SGMT etc

3 · Reply

JarvisFlow Jul. 11 at 12:30 PM

Baird has updated their rating for Soleno Therapeutics ( $SLNO ) to Outperform with a price target of 121.

0 · Reply

Quantumup Jul. 11 at 10:17 AM

Baird⬆️ $SLNO PT to $121 from $105, reiterated Outperform and said, "Positive on launch progress. $RYTM $ACAD $AARD $BIIB RHHBY Baird added, "Soleno's preliminary 2Q results feature impressive Vykat XR sales through the end of June of $31-$33M, in just the first 2.5 months following the mid-April launch. The guided range is well ahead of our/consensus expectations, and coupled with the formidable rate of new start forms, we have further strengthened confidence in Vykat's blockbuster potential. We are revising our price target to $121 accordingly."

1 · Reply

Stocks4thought Jul. 10 at 5:31 PM

$IMMX its a win $3 by Monday latest= This is a major win for Immix Biopharma. The data is highly promising and, if confirmed in a larger cohort, could position NXC-201 as a first-in-class, practice-changing therapy for R/R AL Amyloidosis. ot $SLNO

0 · Reply

Stocks4thought Jul. 10 at 4:39 PM

$IMMX https://www.youtube.com/watch?v=qsaTFcXVCNU&ab_channel=AC%2FDC-Topic $SLNO

0 · Reply

Doozio Jul. 10 at 4:35 PM

$SLNO 2ndry on a 🐑 Thursday TTWO get BYRNed?

0 · Reply

TeeMan123 Jul. 10 at 1:35 PM

$RYTM — Quick elaboration: current ~$5.5B market cap reflects HO/BBS only. There’s no value being ascribed to Prader-Willi yet. And we know Meeker — the GOAT doesn’t greenlight a trial unless he’s confident in efficacy. They've learned a lot about the drug, and he has strong conviction it’ll work in Prader. Meanwhile, $SLNO is a Prader-only story and it’s valued at ~$4.5B. By raising funds, Meeker is signaling he wants Prader priced into $RYTM. If the Phase 1 reads out positively by year-end, the stock could add $2–3B in value — taking it to ~$135/share.

0 · Reply

briefingcom Jul. 10 at 12:59 PM

$SLNO: Soleno Therapeutics provides Q2 guidance update; proposes $200 million public offering of common stock https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20250710060400SLNO&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

OpenOutcrier Jul. 10 at 12:47 PM

$SLNO (-2.8% pre) Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock https://ooc.bz/l/69577

0 · Reply

Quantumup Jul. 10 at 12:19 PM

Stifel reiterated $SLNO Buy-$115 and said " $SLNO reported preliminary 2Q results, including Vykat revenue expectations in the ~$31-$33MM range, and ~646 start-forms from 295 unique prescribers." $AARD $RYTM $ACAD $BIIB HRMY Stifel additionally said:

0 · Reply

CrispDry Jul. 10 at 11:53 AM

$SLNO literally was gonna sell my calls at open and they pre announce and do a raise. Ugh

0 · Reply

Market Cap	4.36B
Revenue (ttm)	0.00
Net Income (ttm)	-175.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.21

Volume	1,036,800
Avg Vol	1,142,386
Day's Range	N/A - N/A
Shares Out	50.39M
Stochastic %K	44%
Beta	-2.63
Analysts	Strong Sell
Price Target	$115.12